<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223821</url>
  </required_header>
  <id_info>
    <org_study_id>B2899-R</org_study_id>
    <nct_id>NCT00223821</nct_id>
  </id_info>
  <brief_title>Enhancing Conservative Treatment for Urge Incontinence</brief_title>
  <acronym>COMBO</acronym>
  <official_title>Enhancing Conservative Treatment for Urge Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this project is to evaluate whether enhancing drug therapy with
      components of behavioral training, including pelvic floor muscle rehabilitation, results in
      better outcomes than drug therapy alone for urge incontinence in community-dwelling women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary incontinence in women is a major problem with significant medical, psychological, and
      social consequences. Previous research on urge incontinence, a common form of incontinence,
      has demonstrated that behavioral and drug interventions are effective, but do not cure most
      patients. Thus there is a need to improve conservative treatment for urge incontinence in
      women. The primary objective of this project is to evaluate whether enhancing drug therapy
      with components of behavioral training, including pelvic floor muscle rehabilitation, results
      in better outcomes than drug therapy alone for urge incontinence in community-dwelling women.
      This project is a randomized controlled clinical trial. Sixty-four women with predominantly
      urge incontinence have been randomized. Stratification and blocked randomization procedures
      are used to assign a subject to 8 weeks of drug therapy alone or 8 weeks of drug therapy
      enhanced with components of behavioral training that can be administered in most any
      outpatient clinic. The drug therapy is extended release oxybutynin, a well-established
      pharmacologic agent with a state of the art drug delivery system that has the lowest rates of
      side-effect. The behavioral treatment is an innovative, comprehensive, behavioral training
      program, which includes pelvic floor muscle rehabilitation, teaching urge suppression and
      other skills to improve bladder control, and self-monitoring with bladder diaries. Bladder
      diaries completed by subjects before and after the treatment are used to calculate reduction
      in the frequency of incontinence. Secondary outcomes measures include a patient satisfaction
      questionnaire and three impact/quality of life measures (Incontinence Impact Questionnaire,
      Uro-Genital Distress Index, SF-12 Health Survey). The second objective of the study is to
      examine the cost-effectiveness of adding behavioral components to drug therapy. With the
      changing health care environment, there is increased concern with the costs of providing
      treatment. This project will compare the relative costs and value of combined intervention
      using the methods of cost-effectiveness analysis, the most widely adopted method for the
      economic evaluation of health interventions. The third objective of the study is to examine
      further the mechanisms by which these therapies reduce incontinence, including changes in
      bladder capacity, thresholds for bladder sensation, pelvic muscle strength, use of pelvic
      muscles in response to the sensation of urgency and frequency of urination. Pre-post changes
      in these parameters are measured to examine the effects of the treatment on these variables,
      and structural equation modeling will be used to examine whether changes in each of these
      measures are related to treatment outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Incontinent Episodes Immediately Post-treatment</measure>
    <time_frame>Baseline and immediately post-treatment - week 8</time_frame>
    <description>Percent change from baseline in weekly frequency of incontinent episodes immediately post-treatment, derived from baseline and week 8 seven-day bladder diaries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Incontinent Episodes at 12-month Follow-up</measure>
    <time_frame>Baseline and 12 months post-treatment</time_frame>
    <description>Percent change from baseline in weekly frequency of incontinent episodes at 12-months post-treatment, derived from baseline and 12-month seven-day bladder diaries</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Drug Therapy Aone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxybutynin chloride, extended-release, individually-titrated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Therapy + Behavioral Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin chloride, extended-release, individually-titrated</intervention_name>
    <description>Individually-titrated, extended-release oxybutynin chloride with management of side-effects.</description>
    <arm_group_label>Drug Therapy Aone</arm_group_label>
    <arm_group_label>Drug Therapy + Behavioral Training</arm_group_label>
    <other_name>Ditropan XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavior Training</intervention_name>
    <description>Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.</description>
    <arm_group_label>Drug Therapy + Behavioral Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants in this study were ambulatory, community-dwelling women (veterans and
        nonveterans) with persistent urge or predominantly urge incontinence.

        Participants must:

          1. Be ambulatory.

          2. Be able to come to the clinic for treatment.

          3. Report urge incontinence.

          4. Report incontinence occurring at least twice per week on average.

          5. Report incontinence persisting for at least three months.

          6. Not have received behavioral therapy in the University of Alabama at Birmingham (UAB)
             Continence Clinic or Department of Veterans Affairs (VA) Continence Clinic.

          7. In the clinical interview, the subject must report involuntary loss of urine
             associated with a strong desire to void and that the condition has persisted for at
             least three months.

          8. At least two urge accidents on the 7-day baseline bladder diary, and the number of
             urge accidents must exceed the number of other types of accidents.

          9. On urodynamic evaluation, there must be cystometric evidence of bladder dysfunction,
             either: detrusor instability or maximal cystometric capacity is less than 400 ml.

        Exclusion Criteria:

          1. Continual leakage.

          2. Urinary tract infection (defined as growth of greater than 10,000 colonies per ml of a
             urinary pathogen on urine culture).

          3. Fecal impaction.

          4. Uncontrolled metabolic problem.

          5. Post-void residual volume &gt; 150 ml.

          6. Hematuria on microscopic examination in the absence of infection. A urologic
             consultation will be recommended and enrollment will depend on agreement between the
             urologist and geriatrician (co-PI) that entry into treatment protocol is not
             contraindicated.

          7. Severe uterine prolapse (prolapse reaching the vaginal introitus).

          8. Decompensated congestive heart failure, diagnosed by history or physical exam.

          9. Impaired mental status. (&lt;24 on Folstein's Mini-Mental State Exam).

         10. Uncontrolled narrow angle glaucoma.

         11. Gastric retention (by medical history).

         12. Hypersensitivity to oxybutynin.

         13. Current use of anticholinergic agents for detrusor instability. Subjects on these
             medications will be asked to discontinue them for the duration of the study.
             Evaluation will be delayed until the drug(s) have been discontinued for 2 weeks.

         14. If on diuretic, dose stable for less than three months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn L. Burgio, PhD MA BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Office of Research and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham VA Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Burgio KL, Goode PS, Richter HE, Markland AD, Johnson TM 2nd, Redden DT. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. J Urol. 2010 Aug;184(2):598-603. doi: 10.1016/j.juro.2010.03.141. Epub 2010 Jun 19.</citation>
    <PMID>20639023</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>October 11, 2013</results_first_submitted>
  <results_first_submitted_qc>October 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2013</results_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Behavior Therapy</keyword>
  <keyword>Behavioral Medicine</keyword>
  <keyword>Behavioral Research</keyword>
  <keyword>Behavioral Sciences</keyword>
  <keyword>Combined Modality Therapy</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Overactive bladder</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Urge incontinence</keyword>
  <keyword>Urinary incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were community-dwelling women with urge predominant incontinence recruited between July 2003 and January 2008.</recruitment_details>
      <pre_assignment_details>Of the 166 women enrolled, 58 were found to be ineligible on clinical evaluation, 44 withdrew, and 64 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drug Therapy Alone</title>
          <description>drug therapy alone
Oxybutynin chloride, extended-release: Individually-titrated, extended-release oxybutynin chloride with management of side-effects.</description>
        </group>
        <group group_id="P2">
          <title>Drug Therapy + Behavioral Training</title>
          <description>drug therapy + behavioral training
Oxybutynin chloride, extended-release: Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
Behavior Training: Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Therapy</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Post-treatment Assessment</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 6-month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>drug therapy alone
Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>drug therapy + behavioral training
Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.
Behavior Training : Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="11.2"/>
                    <measurement group_id="B2" value="57.4" spread="12.6"/>
                    <measurement group_id="B3" value="58.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incontinence type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Urge only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed urge + stress</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incontinence severity</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild (less than 5 episodes/wk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate (5-10 episodes/wk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (&gt; 10 episodes/wk)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Incontinent Episodes Immediately Post-treatment</title>
        <description>Percent change from baseline in weekly frequency of incontinent episodes immediately post-treatment, derived from baseline and week 8 seven-day bladder diaries.</description>
        <time_frame>Baseline and immediately post-treatment - week 8</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Therapy Alone</title>
            <description>Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy + Behavioral Training</title>
            <description>Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.
Behavior Training : Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Incontinent Episodes Immediately Post-treatment</title>
          <description>Percent change from baseline in weekly frequency of incontinent episodes immediately post-treatment, derived from baseline and week 8 seven-day bladder diaries.</description>
          <population>Intention to treat</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-88.5" spread="24.0"/>
                    <measurement group_id="O2" value="-78.3" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effectiveness of each intervention was calculated by comparing the weekly frequency of incontinent episodes (derived from seven-day bladder diaries) during baseline to that in the immediate post-intervention period (week 8). The primary analysis was based on intent-to-treat, in which post-treatment frequency of incontinence for non-completers was derived from the most recent week of diaries.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.16</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA, with baseline frequency of incontinent episodes as the covariate, was used to compare the treatment groups.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>25.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Incontinent Episodes at 12-month Follow-up</title>
        <description>Percent change from baseline in weekly frequency of incontinent episodes at 12-months post-treatment, derived from baseline and 12-month seven-day bladder diaries</description>
        <time_frame>Baseline and 12 months post-treatment</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Therapy Alone</title>
            <description>Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.</description>
          </group>
          <group group_id="O2">
            <title>Drug Therapy + Behavioral Training</title>
            <description>Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.
Behavior Training : Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Incontinent Episodes at 12-month Follow-up</title>
          <description>Percent change from baseline in weekly frequency of incontinent episodes at 12-months post-treatment, derived from baseline and 12-month seven-day bladder diaries</description>
          <population>Intention to treat</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.0" spread="26.1"/>
                    <measurement group_id="O2" value="-75.2" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.37</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA, with baseline frequency of incontinent episodes as the covariate, was used to compare the treatment groups.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.73</ci_lower_limit>
            <ci_upper_limit>24.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>drug therapy alone
Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>drug therapy + behavioral training
Extended release Oxybutynin Chloride : Individually-titrated, extended release oxybutynin chloride with management of side-effects.
Behavior Training : Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Secondary objectives could not be achieved because, based on a conditional power calculation, the trial was stopped early for futility.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathryn L. Burgio, PhD</name_or_title>
      <organization>Birmingham VA Medical Center</organization>
      <phone>205-558-7064</phone>
      <email>kburgio@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

